Vectura Limited Pays A Whopping $181 Million For Activaero

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Vectura Group Plc.(VEC.L) announced the acquisition of Activaero GmbH for a total consideration of 130 million euros or 108 million pounds to be funded through a combination of existing cash and equity. Activaero is a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases. Its proprietary smart nebuliser-based technology (FAVORITE) allows drug deposition into targeted areas of the lung and is currently utilised in seven clinical and several preclinical stage programmes.

Help employers find you! Check out all the jobs and post your resume.

Back to news